Market Intelligence, Clinical Progress, and High-Purity Reagents for B-cell Malignancy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD37 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (ECD-Fc & Membrane Prep) | CD37 ECD-Fc Fusion Protein (>95% purity, Endotoxin <1EU/µg) and Lentivirus/Membrane Prep for native tetraspanin conformation. | View CD37 Products |
| Gene Delivery | CD37 Lentivirus Premade Particles (Full-length ORF for stable cell lines). Preserves native glycosylation and membrane topology. | View CD37 Products |
| Benchmark Ab | Anti-CD37 (Sequence of Otlertuzumab/TRU-016, Naratuximab, and Lilotomab). Recombinant positive controls for binding and internalization. | View CD37 Products |
| Validator | CD37 siRNA Set (≥80% knockdown efficiency) for specificity control and false-positive elimination. | View CD37 Products |
| Related Target: CD19 | Pan‑B cell marker; synergistic combination target for dual-targeting strategies (CAR‑T, bispecific). | View CD19 Products |
| Related Target: CD20 | Established B-cell oncology benchmark; essential for combination therapy assays and SOC comparisons. | View CD20 Products |
| Related Target: CD53 | Tetraspanin family member; critical for off-target selectivity screening. | View CD53 Products |
| Related Target: CD79b | High-potential B‑cell ADC target (e.g., Polatuzumab); for internalization efficiency comparison and synergy mechanism studies. | View CD79b Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Tetraspanin Conformation (4‑TMD structure) | Lentivirus for stable cell line construction; preserves native glycosylation and membrane topology for internalization assays. |
| Internalization Rate Quantification (ADC payload delivery) | High-purity ECD‑Fc (>95%) with validated sequence for SPR‑based binding kinetics and FACS internalization studies. |
| Lack of Controls for Clinical Benchmarking | Sequence‑verified biosimilar antibodies (Otlertuzumab, Naratuximab, Lilotomab) included. |
| Tetraspanin Family Selectivity (CD53, CD81, CD82) | Ortholog panel proteins available; sequence‑verified by mass spec for counter‑screening. |
| Cross‑species Cyno/Mouse Toxicology | Human/Cynomolgus ortholog ECD proteins with endotoxin <1EU/µg for GLP‑compliant immunogenicity screening. |
| False Positives in Binding Assays | CD37 siRNA included for specificity verification via knockdown validation. |
Live CD37 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD37 therapeutics is intensifying. Major players are shifting focus from naked antibodies to Antibody‑Drug Conjugates (ADCs), radioimmunotherapy, and bispecific T‑cell engagers. As first‑generation therapies targeting CD20 and CD19 face relapse, CD37 is emerging as a high‑value target due to its stable, high expression on malignant B‑cells. Key pipelines include Boehringer Ingelheim’s BI 836826 (ADC, phase II), Debiopharm’s Naratuximab emtansine (ADC), Nordic Nanovector’s Betalutin (radiolabeled Lilotomab), and Aptevo’s Otlertuzumab (fusion protein). The next wave of R&D focuses on resistance mechanisms through combination regimens with CD20 inhibitors, BCL‑2 inhibitors, and novel payload technologies.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Boehringer Ingelheim, Debiopharm, ImmunoGen, Agensys/Astellas | NHL, CLL, DLBCL, Follicular Lymphoma | Internalization assay (need high‑purity ECD‑Fc and lentivirus stable cells); payload delivery quantification. |
| Fusion Protein | Aptevo (Otlertuzumab/TRU‑016) | CLL, MCL | Cell‑based binding (need full‑length lentivirus); ADCC reporter assays. |
| Radioimmunotherapy | Nordic Nanovector (Betalutin) | Follicular Lymphoma | High‑affinity binding requiring native tetraspanin structural integrity. |
| Bispecific / CAR‑T | Novartis, Genmab, emerging biotechs | Refractory B‑cell malignancies | Synapse formation (need accurate surface expression); heterodimer validation (need cross‑reactive antibodies). |
| Naked mAb | Preclinical | Autoimmune (SLE) | Apoptosis induction assays; cross‑species epitope mapping. |